Ozempic Gastroparesis Attorney: Statute of Limitations for Ozempic in North Carolina

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Legal Guidance

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical conditions, treatment options, and preventive care. This legacy heritage emphasized broad awareness of wellness principles and the importance of informed decision-making in healthcare. As scientific knowledge advances, the same informational framework must adapt to address emerging therapeutic applications and their associated considerations. In recent years, the introduction of glucagon-like peptide-1 receptor agonists, such as Ozempic, has expanded treatment horizons for metabolic disorders. This development naturally shifts the focus from general health education to more specific exposure contexts. Individuals prescribed these medications may encounter unanticipated physiological responses that warrant careful monitoring. The transition from general health awareness to occupational exposure concern arises when patients or their representatives seek to understand the legal implications of adverse outcomes. Specifically, in North Carolina, the statute of limitations for claims related to Ozempic exposure and gastroparesis risk becomes a critical consideration. This pivot from broad health information to targeted legal inquiry reflects the evolving needs of those affected by pharmaceutical interventions. The informational heritage now serves as a bridge to practical, actionable guidance for individuals navigating the intersection of medical treatment and legal recourse.

Understanding Ozempic and Its Gastrointestinal Effects

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for weight management. Its mechanism of action includes slowing gastric emptying, which can lead to gastrointestinal adverse effects. Gastroparesis, a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, presents with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy or breath testing. The overlap between Ozempic's pharmacodynamic effects and gastroparesis symptoms raises concern about a causal link. Clinical trial data from the Ozempic prescribing information show that gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo. In the pool of placebo-controlled trials, gastrointestinal adverse reactions were reported in 15.3% of placebo patients, 32.7% of those on Ozempic 0.5 mg, and 36.4% of those on Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. Discontinuation due to gastrointestinal adverse reactions occurred in 3.1% of patients on Ozempic 0.5 mg and 3.8% on Ozempic 1 mg, compared to 0.4% on placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently with the 2 mg dose (34.0%) versus 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal adverse effects, which are consistent with delayed gastric emptying.

Mechanistic Link and Postmarketing Concerns

Mechanistically, GLP-1 receptor agonists like Ozempic slow gastric motility by inhibiting vagal nerve activity and reducing antral contractions. This pharmacologic effect can mimic or exacerbate gastroparesis. Postmarketing reports have raised concerns about pulmonary aspiration in patients undergoing elective surgeries or procedures requiring general anesthesia or deep sedation, due to residual gastric contents despite adherence to preoperative fasting recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This suggests that Ozempic can cause clinically significant delays in gastric emptying, potentially leading to gastroparesis-like symptoms. The prescribing information notes that available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration, including whether modifying preoperative fasting or temporarily discontinuing Ozempic could reduce the incidence of retained gastric contents (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This underscores the uncertainty regarding the drug's effect on gastric motility in individual patients.

Legal Considerations for North Carolina Patients

For patients in North Carolina who have developed gastroparesis after using Ozempic, legal considerations include the statute of limitations for product liability claims. In North Carolina, the statute of limitations for personal injury claims is generally three years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. For claims involving defective drugs, the timeline may be affected by when the patient became aware of the link between Ozempic and their gastroparesis symptoms. The adequacy of warnings is a key risk factor. The Ozempic label does not explicitly list gastroparesis as a warning or adverse reaction, though it does describe gastrointestinal adverse reactions and the risk of pulmonary aspiration due to retained gastric contents (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). Patients may argue that the warnings were insufficient to alert them to the risk of developing gastroparesis, especially given that the drug's mechanism directly involves delayed gastric emptying. The timeline between exposure to Ozempic and documented harm is critical. Gastrointestinal adverse reactions often occur during dose escalation, but gastroparesis may develop or persist after prolonged use. Patients should document the start date of Ozempic use, the onset of symptoms such as nausea, vomiting, or abdominal pain, and any diagnostic tests confirming gastroparesis. Medical records showing a temporal relationship between drug initiation and symptom onset strengthen a potential claim. Attorneys may also consider whether the patient was informed of the risk of delayed gastric emptying and whether alternative treatments were discussed. In summary, the evidence from clinical trials and postmarketing reports indicates that Ozempic can cause gastrointestinal adverse effects consistent with gastroparesis, including delayed gastric emptying. The prescribing information acknowledges the risk of retained gastric contents but does not explicitly warn of gastroparesis. Patients in North Carolina should be aware of the three-year statute of limitations and the importance of documenting the timeline of exposure and harm. Consulting with an attorney experienced in pharmaceutical litigation is advisable to evaluate the specifics of each case.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic-related gastroparesis claims in North Carolina?

In North Carolina, the statute of limitations for personal injury claims, including product liability claims related to Ozempic, is generally three years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. For claims involving defective drugs, the timeline may be affected by when the patient became aware of the link between Ozempic and their gastroparesis symptoms.

Does Ozempic's prescribing information warn about gastroparesis?

The Ozempic label does not explicitly list gastroparesis as a warning or adverse reaction, but it does describe gastrointestinal adverse reactions and the risk of pulmonary aspiration due to retained gastric contents (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). Patients may argue that these warnings were insufficient to alert them to the risk of developing gastroparesis.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.